Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT02855944IIIRecurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerView DrugsCalifornia, Colorado, Georgia, Maine, Michigan, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03398655IIIPlatinum resistant ovarian cancerA Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian CancerView DrugsMassachusetts, New York
Drug(s) in Trial Other Drug Names Main Known Action
Ofranergene ObadenovecVB-111Endothelin promoter-apoptotic receptor gene therapy
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02558348IIaPlatinum refractory or persistent ovarian cancer (< 3 prior therapies) with FGFR 1-3 alterationsA Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)View DrugsIllinois, Utah
Drug(s) in Trial Other Drug Names Main Known Action
AL3818VEGFR and FGFR kinase inhibitor
NCT02584478IIaRecurrent ovarian cancerA Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)View DrugsCalifornia, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AnlotinibAL3818VEGFR2/3 kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02419417IIaPlatinum resistant or refractory ovarian cancer with BRCA1/2-mutationsA Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic MalignanciesView DrugsCalifornia, Colorado, Oregon, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986158BET inhibitor BMS-986158BET inhibitor
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02658890IIaAdvanced solid tumors (in expansion)A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsView DrugsArizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986205Inhibits IDO to stimulate immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02091141IIaAdvanced solid tumors with ALK mutations or high TMBMy Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These AgentsView DrugsArizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Tennessee, Texas, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
AlectinibALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802ALK kinase inhibitor
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
NCT02839707II/IIIPlatinum resistant ovarian cancerA Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian CancerView DrugsAlaska, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitor
NCT01037790IIAdvanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterationsPhase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
NCT01953926IIAdvanced solid tumors with activating HER2 mutationsAn Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.View DrugsArizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NeratinibHKI-272, PD272EGFR, HER2, HER4 kinase inhibitor
NCT02203513IIRecurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancerA Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
PrexasertibLY2606368, checkpoint kinase 1 inhibitor LY2606368Chk1/2 inhibitor
NCT02312245IIPlatinum resistant or refractory ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
TopotecanTOPO, Hycamtin, HycamptamineTopoisomerase I inhibitor
NCT02272998IIAdvanced Solid Tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterationsPhase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)View DrugsMichigan, Ohio
Drug(s) in Trial Other Drug Names Main Known Action
Ponatinibmultitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534Multi-targeted kinase inhibitor
NCT02079740IIAdvanced solid tumors with KRAS or NRAS mutations (in expansion)An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
NavitoclaxBcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263Bcl-2, Bcl-XL, and Bcl-w inhibitor
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
NCT02484404IIPlatinum resistant or refractory ovarian cancer ( > 2 prior platinum therapies)Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02485990IIPlatinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)View DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02571725IIRecurrent ovarian cancer with germline BRCA1/2 mutationsA Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian CancerView DrugsFlorida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsView DrugsArizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New York, North Carolina, Ohio, Oklahoma, Oregon, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101ALK, TRK, ROS1 kinase inhibitor
NCT02595892IIPlatinum resistant high grade serous ovarian cancer (only 1 prior therapy for platinum resistant disease)Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube CancerView DrugsArizona, California, Florida, Massachusetts, Michigan, Minnesota, Pennsylvania, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
NCT02608684IIPlatinum resistant ovarian cancerA Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian CancerView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinPlatosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACPDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02693535IIAdvanced solid tumors with defined molecular alterations (VEGFR, Bcr-abl, SRC, LYN, LCK, ALK, ROS1, MET,CDKN2A/p16, CDK4, CDK6, CSF1R, PDGFR, mTOR, TSC, ERBB2, BRAFV600E, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, BRCA1/BRCA2, ATM, POLD, POLE, highTMB)Targeted Agent and Profiling Utilization Registry (TAPUR) StudyView DrugsAlabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AxitinibInlyta, AG-013736Multi-targeted RTK inhibitor
BosutinibBosulif, SKI-606Abl and src family kinase inhibitor
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
CobimetinibCotellic, GDC-0973, XL518MEK1 inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
DasatinibBMS-354825, SprycelSRC and bcr-abl kinase inhibitor
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitor
Sunitinib Sunitinib malate, SutentVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TemsirolimusCCI-779, ToriselmTOR inhibitor
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonist
VemurafenibZelboraf, PLX4032, RO5185426BRAF kinase inhibitor
NCT02465060IIAdvanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2Molecular Analysis for Therapy Choice (MATCH)View DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitor
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitor
Erdafitinibpan-FGFR tyrosine kinase inhibitor JNJ-42756493pan-FGFR kinase inhibitor
LarotrectinibTrk inhibitor LOXO-101Pan-Trk kinase inhibitor
OsimertinibTagrisso, AZD9291, EGFR inhibitor AZD9291, MereletinibEGFR kinase inhibitor
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitor
SapanisertibTAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128TORC1/2 kinase inhibitor
Sunitinib Sunitinib malate, SutentVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit
TrametinibMekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212MEK1/2 inhibitor
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonist
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonist
NCT02628067IIAdvanced solid tumors with high MSIA Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)View DrugsCalifornia, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02576444IIAdvanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutationsA Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid TumorsView DrugsConnecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
AZD6738ATR kinase inhibitor
CapivasertibAkt inhibitor AZD5363pan-AKT inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02785250IIRecurrent ovarian cancerA Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian CancerView DrugsCalifornia, Georgia, New York, Oregon, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
DPX-Survivacsurvivin antigen vaccine DPX-SurvivacImmune response against cancer expressing survivin
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO to stimulate immune response
NCT01325441IIPlatinum resistant or refractory ovarian cancer (< 4 prior cytotoxic therapies)A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced MalignanciesView DrugsIndiana
Drug(s) in Trial Other Drug Names Main Known Action
Napabucasincancer stemness inhibitor BBI608, BBI608STAT3 and cancer stemness inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02554812IIAdvanced solid tumors (in ovarian expansion)A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced MalignanciesView DrugsCalifornia, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitor
PF-04518600 anti-OX40 antibody PF-04518600Stimulates OX40 to increase T cell activation and immune response
NCT02832167IIAdvanced solid tumorsAn Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic MalignanciesView DrugsArizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT01690468IIPlatinum resistant or persistent ovarian cancerA Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian CancerView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
TriciribineTCN-PM, PTX-200, tricycloside phosphate, tricyclic nucleoside, triciribine phosphate, API-2, TCN, NSC 154020, Akt/PKB Signaling Inhibitor-2, Inhibitor V, VD-0002AKT phosphorylation inhibitor
NCT02873975IIAdvanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutationsA Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair DeficiencyView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
PrexasertibLY2606368, checkpoint kinase 1 inhibitor LY2606368Chk1/2 inhibitor
NCT01851369IIAdvanced solid tumors and granulosa cell ovarian cancer (in expansion)A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
methoxyamineTRC102Base excision repair inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT02889900IIPlatinum resistant ovarian cancer without germline BRCA1/2 mutations (at least 3 prior therapies)A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA MutationView DrugsAlabama, Alaska, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana, Maryland, Massachusetts, Michigan, Montana, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02901899IIPlatinum resistant ovarian cancerAn Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian CancerView DrugsIllinois
Drug(s) in Trial Other Drug Names Main Known Action
GuadecitabineDNA methyltransferase inhibitor SGI-110, SGI-110DNA methylation inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02432378IIPlatinum sensitive ovarian cancer with first recurrence in peritoneal cavityA Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 VaccinesView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Alpha-DC1 vaccineAnti-tumor immune response
CelecoxibCelebrex
CisplatinPlatosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACPDNA damaging agent
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT02675829IIAdvanced solid tumors with HER2 amplificationA Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
Trastuzumab emtansineado trastuzumab emtansine, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1 immunoconjugateADC: anti-HER2 + microtubule destabilizer (DM1)
NCT01697527IIAdvanced NY-ESO-1+ solid tumorsAdoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitor
NY-ESO-1 reactive TCR retroviral vector transduced autologous PBLanti-NY-ESO-1 TCR gene-engineered lymphocytesImmune response against cancer expressing NY-ESO-1
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccineImmune response against cancer expressing NY-ESO-1
NCT02948101IIPlatinum resistant or refractory ovarian cancerPilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CyclophosphamideCiclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, SendoxanDNA damaging agent
PD-0360324anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324CSF1R antagonist and tumor-associated macrophage inhibitor
NCT02608268IIAdvanced solid tumors (in expansion)Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced MalignanciesView DrugsMaryland, Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
MBG453Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM3 Checkpoint Inhibitor MBG453Blocks TIM-3 inhibition of T cells
PDR001anti-PD-1 monoclonal antibody PDR001Blocks PD-L1/2 inhibition of T cells
NCT02834013IIAdvanced ovarian germ cell, mucinous, squamous cell, or adenocarcinomaDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsView DrugsAlabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02900560IIPlatinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsCalifornia, Maryland, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
Oral AzacitidineCC-486DNA methylation inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02843165IIAdvanced solid tumors with lesion treatable with radiotherapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02983799IIPlatinum sensitive recurrent ovarian cancer (> 1 prior therapy)Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of ChemotherapyView DrugsAlaska, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03026062IIPlatinum resistant or refractory ovarian cancerRandomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT03093155IIPlatinum resistant, refractory or persistent ovarian cancerA Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersView DrugsConnecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
IxabepiloneAzaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, IxempraMicrotubule stabilizer/mitotic inhibitor
NCT02354131IIPlatinum sensitive, recurrent high grade serous or endometrioid ovarian cancerPart 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
NiraparibMK4827, ZejulaPARP inhibitor
NCT02920996IIAdvanced solid tumors with NTRK1-3 rearrangementsA Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK RearrangementsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
Merestinibc-Met inhibitor LY2801653, LY2801653Multi-targeted RTK inhibitor
NCT03073525IIAdvanced high grade serous, clear cell, or endometrioid ovarian cancerA Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological CancersView DrugsAlabama, Georgia, Michigan, Montana, New Hampshire, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
Gemogenovatucel-TVigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccineImmune cell stimulator and TGFbeta inhibitor
NCT02587598IIAdvanced solid tumors (in expansion)A Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesView DrugsArizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, New York, Oklahoma, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Azacytidineazacitidine, Vidaza, Mylosar, 5-AZCDNA methylation inhibitor
INCB053914pan-PIM inhibitor INCB053914PIM1, 2, 3 inhibitor
NCT03113487IIPlatinum resistant ovarian cancer (<4 prior cytotoxic therapies)P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
MVA-p53 vaccineModified Vaccinia Virus Ankara Vaccine Expressing p53, p53MVA, p53MVA vaccineImmune response against p53 tumor antigen
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03253679IIAdvanced solid tumors with CCNE1 AMPA Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 AmplificationView DrugsNew York, North Carolina, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03029611IINewly diagnosed stage III-IV ovarian cancer (neo-adjuvant)A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive SurgeryView DrugsWashington
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
IGFBP-2 vaccinepUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA VaccineImmune response against cancer expressing IGFBP-2
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03274661IIAdvanced solid tumorsEvaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair DeficiencyView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03146663IIPlatinum resistant high grade serous or endometrioid ovarian cancer (at least 3 prior therapies)A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian CancerView DrugsArizona, California, Colorado, Florida, Illinois, Minnesota, Missouri, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
NUC-1031gemcitabine ProTide, Acelarin, gemcitabine-phosphoramidate NUC-1031Ribonucleotide reductase and DNA synthesis inhibitor
NCT03284385IIAdvanced solid tumors with SETD2 deficiencyA Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesView DrugsCalifornia, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
NCT03300843IIAdvanced solid tumors (with resectable tumor)A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerView DrugsMaryland
Drug(s) in Trial Other Drug Names Main Known Action
Peptide loaded dendritic cell vaccineAnti-tumor immune response
NCT03310879IIAdvanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplificationsA Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6View DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibVerzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, BemaciclibCDK4/6 inhibitor
NCT03348631IIRecurrent or persistent endometrioid/clear cell ovarian cancerA Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial AdenocarcinomaView DrugsContact Research Staff
Drug(s) in Trial Other Drug Names Main Known Action
Tazemetostathistone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438EZH2 histone methyltransferase inhibitor
NCT03355976IIRecurrent clear cell ovarian cancerBrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasView DrugsRhode Island
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03342417IIPlatinum resistant or refractory ovarian cancerPhase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer PatientsView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03312114IIRecurrent or persistent ovarian cancer (tumor amenable to radiation)Phase II Trial of Concurrent Anti—PD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)View DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NCT03147976IIAdvanced solid tumors with MET over-expression or mutationA Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) MutationsView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AMG 337c-Met kinase inhibitor
NCT03395080IIPlatinum resistant or refractory ovarian cancerA Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian CancerView DrugsAlabama, Arizona, Florida, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
DKN-01DKK1-neutralizing monoclonal antibody DKN-01Dickkopf-1 (DKK1) antagonist
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03414047IIPlatinum resistant or refractory high grade serous ovarian cancerA Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian CancerView DrugsArizona, California, Florida, Massachusetts, Missouri, New Hampshire, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington
Drug(s) in Trial Other Drug Names Main Known Action
PrexasertibLY2606368, checkpoint kinase 1 inhibitor LY2606368Chk1/2 inhibitor
NCT03365791IIAdvanced solid tumorsModular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.View DrugsCalifornia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Maryland, Montana, Nebraska, Nevada, North Carolina, Oregon, Pennsylvania, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
LAG525anti-LAG-3 monoclonal antibody LAG525Blocks LAG-3 inhibition of T cells
PDR001anti-PD-1 monoclonal antibody PDR001Blocks PD-L1/2 inhibition of T cells
NCT03428802IIAdvanced solid tumors with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityView DrugsNew Jersey
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03456700IIRecurrent serous ovarian cancerPhase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent DiseaseView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
AuranofinRidauraThioredoxin reductase inhibitor
SirolimusRapamune, RapamycinmTOR inhibitor
NCT03462342IIRecurrent ovarian cancerCombination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerView DrugsPennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT01876511IIAdvanced solid tumors with positive MSI or tumors with negative MSI and high TMBPhase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) TumorsView DrugsCalifornia, Maryland, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03570619IIAdvanced solid tumors with CDK12 alterationsIMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsView DrugsMichigan
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03565991IIAdvanced solid tumors with BRCA1/2 or ATM mutationsA Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant TumorsView DrugsCalifornia, Georgia, Massachusetts, Missouri, New Jersey, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibMDV3800, BMN-673, Talazoparib TosylatePARP inhibitor
NCT03579316IIPlatinum resistant or refractory ovarian cancer (PD on prior PARP inhibitor)A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP InhibitionView DrugsMassachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03602586IIRecurrent or persistent clear cell ovarian cancerA Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the OvaryView DrugsAlaska, California, Georgia, Idaho, Illinois, Indiana, Iowa, Maryland, Minnesota, Missouri, Montana, Nebraska, Nevada, Ohio, Oklahoma, Oregon, Rhode Island, Virginia, Washington, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO to stimulate immune response
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03610490IIRecurrent or refractory high grade serous ovarian cancer or carcinosarcomaClinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
MDA-TILautologous tumor-infiltrating lymphocytes MDA-TILAnti-tumor immune response
NCT03651271IIRecurrent ovarian cancer with high MSIAn Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03668119IIAdvanced solid tumors with high TMBA Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)View DrugsCalifornia, Colorado, Florida, Illinois, Indiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03587311IIPlatinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancerA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
Anetumab ravtansineBAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343ADC: anti-mesothelin + microtubule destabilizer (DM4)
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03682289IIRecurrent ovarian cancerPhase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor MalignanciesView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
AZD6738ATR kinase inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT03574779IIPlatinum resistant ovarian cancerPhase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian CancerView DrugsMassachusetts, Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
NiraparibMK4827, ZejulaPARP inhibitor
TSR-042ANB011, anti-PD-1 monoclonal antibody TSR-042Blocks PD-L1/2 inhibition of T cells
NCT03704467IIPlatinum sensitive epithelial ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies)A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03718091IIAdvanced solid cancer with ATM truncation mutations or other HR gene mutationsA Phase II Study of M6620 (VX-970) in Selected Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingView DrugsCalifornia, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03673124IILow grade serous ovarian cancerA Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumView DrugsContact Research Staff
Drug(s) in Trial Other Drug Names Main Known Action
LetrozoleFemaraAromatase inhibitor
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitor
NCT02683395Ib/IIaAdvanced solid tumorsA Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid TumorsView DrugsOhio
Drug(s) in Trial Other Drug Names Main Known Action
PLX51107BRD4 inhibitor PLX51107BRD4 inhibitor
NCT02759588Ib/IIPlatinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease)Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)View DrugsCalifornia, Florida
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
GL-ONC1light-emitting oncolytic vaccinia virus GL-ONC1Membrane disrupter
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03330405Ib/IIPlatinum sensitive recurrent ovarian cancerA Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid TumorsView DrugsArkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
TalazoparibMDV3800, BMN-673, Talazoparib TosylatePARP inhibitor
NCT03639246Ib/IIPlatinum resistant ovarian cancerA Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian CancerView DrugsCalifornia, Massachusetts, Missouri, Oklahoma, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AVB-S6-500GAS6 antagonist
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03684811Ib/IIAdvanced solid tumors with IDH1 mutations (inc expansion)A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 MutationView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
FT-2102mutated IDH1 inhibitor
NCT02511795IbAdvanced solid tumorsA Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid TumoursView DrugsColorado, Florida, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AdavosertibWEE1 inhibitor AZD1775, MK1775, AZD1775WEE1 inhibitor
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02606305IbAdvanced FRalpha+ ovarian cancer (inc expansion)A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerView DrugsMassachusetts, Ohio, Oklahoma, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
Mirvetuximab SoravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02649673IbRecurrent ovarian cancer (in expansion)Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic MalignanciesView DrugsFlorida, Oklahoma, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
LCL161SMAC mimetic LCL161SMAC mimetic and IAP antagonist
TopotecanTOPO, Hycamtin, HycamptamineTopoisomerase I inhibitor
NCT02551185IbAdvanced solid tumorsA Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid TumorsView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
ACY-241HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241HDAC inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT02751918IbPlatinum resistant mesothelin+ ovarian cancerAn Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsCalifornia, Colorado, Connecticut, Ohio, Oklahoma, Oregon
Drug(s) in Trial Other Drug Names Main Known Action
Anetumab ravtansineBAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343ADC: anti-mesothelin + microtubule destabilizer (DM4)
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitor
NCT02994953IbAdvanced solid tumorsA Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid TumorsView DrugsCalifornia, Connecticut, Florida, Louisiana, Maryland, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
NHS-IL12M9241, immunocytokine NHS-IL12IL-12 receptor agonist
NCT03099174IbAdvanced solid tumorsAn Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion CohortsView DrugsCalifornia, Connecticut, Minnesota, Nevada
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibVerzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, BemaciclibCDK4/6 inhibitor
XentuzumabBI-836845IGF-1/2 antagonist
NCT03239145IbAdvanced solid tumors (inc ovarian expansion)Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorView DrugsMassachusetts
Drug(s) in Trial Other Drug Names Main Known Action
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
TrebananibAMG 386Angiopoietin 1/2 antagonist
NCT03162562IbRecurrent or persistent ovarian cancerProspective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal OriginView DrugsFlorida, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
OregovomabB43.13, Monoclonal Antibody B43.13, OvaRexImmune response against cancer expressing CA125
poly ICLCpoly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLCActivates dendritic cells and induces interferon production
NCT03150810IbAdvanced solid tumors (inc ovarian expansion)A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsMichigan, Missouri, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BGB-290PARP inhibitor BGB-290PARP inhibitor
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agent
NCT03113188IbAdvanced solid tumors (inc expansion)Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory TumorsView DrugsArizona, Louisiana, Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action
CBP501G2 checkpoint inhibitor CBP501G2 checkpoint inhibitor
CisplatinPlatosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACPDNA damaging agent
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03292172IbRecurrent advanced ovarian cancer (inc expansion)Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast CancerView DrugsCalifornia, Massachusetts, Oklahoma, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
RO6870810TEN-010, RG6146, BET inhibitor RO6870810BET inhibitor
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GalunisertibLY2157299TGFBR1 antagonist
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03236935IbAdvanced solid tumors with high MSI or dMMRPhase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
L-NMMApan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginineNOS inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03307785IbAdvanced solid tumors (< 5 prior therapies)Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerView DrugsArizona, California, Florida, Ohio, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
TSR-042ANB011, anti-PD-1 monoclonal antibody TSR-042Blocks PD-L1/2 inhibition of T cells
NCT03168061IbAdvanced solid tumorsA Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaView DrugsCalifornia, Indiana, Missouri, Nevada, New York, North Carolina
Drug(s) in Trial Other Drug Names Main Known Action
NC-6300epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912Topoisomerase II inhibitor
NCT03318445IbAdvanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion)Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA RepairView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitor
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT03319628IbPlatinum resistant ovarian cancer (inc expansion)A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2bView DrugsMassachusetts, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
XMT-1536ADC: anti-NaPi2b + microtubule destabilizer (auristatin)
NCT02304393IbAdvanced solid tumors (in expansion)An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid TumorsView DrugsAlabama, Arizona, California
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
SelicrelumabCD40 agonist monoclonal antibody RO7009789Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response
NCT02660034IbPlatinum sensitive recurrent ovarian cancer (at least 2 prior platinum therapies)A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid TumorsView DrugsArizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BGB-290PARP inhibitor BGB-290PARP inhibitor
Tislelizumabanti-PD-1 monoclonal antibody BGB-A317Blocks PD-L1/2 inhibition of T cells
NCT03558139IbAdvanced solid tumors (inc ovarian expansion)A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum ChemotherapyView DrugsIllinois, Michigan, Oklahoma, Texas
Drug(s) in Trial Other Drug Names Main Known Action
AvelumabAnti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, BavencioBlocks PD-L1 inhibition of T cells
Hu5F9-G4anti-CD47 monoclonal antibody Hu5F9-G4Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis
NCT03586661IbPlatinum resistant or refractory ovarian cancer with BRCA1/2 mutations (except high grade serous)(inc expansion)A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CopanlisibBAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitor
NiraparibMK4827, ZejulaPARP inhibitor
NCT03589651IbAdvanced solid tumors (inc expansion)A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsView DrugsCalifornia, Illinois, North Carolina, Pennsylvania, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO to stimulate immune response
INCB050465PI3K-delta inhibitor INCB050465PI3K delta inhibitor
MGA012anti-PD-1 monoclonal antibody MGA012, INCMGA00012Blocks PD-L1 inhibition of T cells
NCT03601897IbAdvanced solid tumorsAn Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid TumorsView DrugsAlabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
Rebastinibmultitargeted tyrosine kinase inhibitor DCC-2036Multi-targeted kinase inhibitor
NCT03621982IbAdvanced solid tumors (inc expansion)A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid TumorsView DrugsConnecticut, New York, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Camidanlumab Tesirineanti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301DNA damaging agent
NCT03611868IbAdvanced solid tumorsA Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-115p53-HDM2 protein-protein interaction inhibitor APG-115, MDM2-p53 inhibitor APG-115MDM2 inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03650348IbAdvanced HER2+ solid tumors (inc expansion)A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabRG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, TecentriqBlocks PD-L1 inhibition of T cells
PRS-343anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343Immune response against cancer expressing HER2
NCT03209401Ia/IbAdvanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesView DrugsDistrict of Columbia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
NCT03514121Ia/IbAdvanced solid tumors (inc ovarian expansion)A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid TumorsView DrugsArizona, California, Connecticut, Michigan, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
FPA150anti-B7-H4 monoclonal antibody FPA150Immune response against cancer expressing B7-H4, blocks B7-H4 inhibition of T cells
NCT03295942IaAdvanced solid tumorsA Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid TumorsView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
OMP-336B11trimeric GITRL-Fc OMP-336B11GITR (glucocorticoid-induced TNFR) agonist
NCT02913313I/IIaAdvanced solid tumors (inc expansion)Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsNew Jersey, New York, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986207anti-TIGIT monoclonal antibody BMS-986207Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02754141I/IIaAdvanced solid tumors (inc expansion)A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid TumorsView DrugsMaryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986179anti-CD73 monoclonal antibody BMS-986179Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03110107I/IIaAdvanced solid tumors (inc expansion)Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsMassachusetts, New Jersey, New York, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986218Blocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03519178I/IIaPlatinum resistant ovarian cancerPhase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine TherapyView DrugsCalifornia, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action
PF-06873600CDK inhibitor PF-06873600pan-CDK inhibitor
NCT03363776I/IIaAdvanced solid tumors (inc expansion)Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial TumorsView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986277Undisclosed mechanism
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02627443I/IIPlatinum sensitive ovarian cancer at first recurrencePhase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerView DrugsArizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
BerzosertibVX-970, M6620, VE-822, ATR kinase inhibitor VX-970ATR kinase inhibitor
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
NCT02734004I/IIPlatinum sensitive recurrent ovarian cancerA Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors (MEDIOLA)View DrugsMaryland, Massachusetts, Missouri, Ohio, Pennsylvania, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
NCT02762981I/IIAdvanced solid tumors (inc ovarian expansion, < 4 prior therapies,)Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid TumorsView DrugsArizona, California, Illinois
Drug(s) in Trial Other Drug Names Main Known Action
CORT125134GR antagonist
nab-PaclitaxelABI-007, Abraxane, Paclitaxel Albumin-Stabilized Nanoparticle FormulaMicrotubule stabilizer/mitotic inhibitor
NCT02671435I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid TumorsView DrugsAlabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York, Rhode Island, Tennessee, Texas, Utah
Drug(s) in Trial Other Drug Names Main Known Action
CetuximabErbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225EGFR antagonist
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
MonalizumabIPH2201, anti-NKG2A monoclonal antibody IPH2201Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes
NCT02904226I/IIAdvanced solid tumors (inc expansion)Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor MalignanciesView DrugsCalifornia, Colorado, Connecticut, District of Columbia, Illinois, Massachusetts, Missouri, New Jersey, New York, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
JTX-2011ICOS agonist monoclonal antibodyStimulates ICOS to increase T cell activity and immune response
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02068794I/IIRecurrent or progressive ovarian cancerPhase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysis
NCT02953457I/IIRecurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancerA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cells
NCT02963831I/IIPlatinum resistant or refractory ovarian cancer (with peritoneal disease)A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesView DrugsFlorida, New York, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
ONCOS-102Anti-tumor immune response
NCT03013491I/IIAdvanced solid tumors (inc expansion)An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or LymphomasView DrugsArizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CX-072Blocks PD-L1 inhibition of T cells
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
VemurafenibZelboraf, PLX4032, RO5185426BRAF kinase inhibitor
NCT03029598I/IIPlatinum resistant ovarian cancer (at least 1 non-platinum therapy)Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsWashington
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03162627I/IIRecurrent ovarian cancer with Ras pathway alterations or PARP inhibitor resistanceEvaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP ResistanceView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
OlaparibAZD2281, LynparzaPARP inhibitor
SelumetinibAZD6244, ARRY-142886MEK inhibitor
NCT03251924I/IIAdvanced solid tumorsA Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsView DrugsMassachusetts, New Jersey, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986226anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226Stimulates ICOS to increase T cell activity and immune response
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02587962I/IIAdvanced solid tumors (inc expansion)A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid TumorsView DrugsCalifornia, Florida, Maryland, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action
BirinapantSmac Mimetic TL32711, TL32711SMAC mimetic and IAP antagonist
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03281681I/IIPlatinum resistant recurrent ovarian cancer (< 5 prior therapies; at least 2 platinum regimens)A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian CancerView DrugsArizona, Michigan, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action
VAL-083bi-functional alkylating agent VAL-083DNA damaging agent
NCT03260322I/IIAdvanced solid tumors (inc expansion)A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsView DrugsArizona, California, Florida, Iowa, New York, Pennsylvania, Tennessee, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
ASP8374PTZ-201Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03149549I/IIAdvanced solid tumorsA Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)View DrugsCalifornia, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CX-2009anti-CD166 probody-drug conjugate CX-2009, PDC CX-2009, anti-CD166-DM4 CX-2009, ADC CX-2009ADC: anti-CD166 + microtubule destabilizer (DM4)
NCT03314935I/IIAdvanced solid tumorsA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid TumorsView DrugsAlabama, California, Georgia, Texas
Drug(s) in Trial Other Drug Names Main Known Action
CisplatinPlatosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACPDNA damaging agent
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitor
INCB001158CB-1158, Arginase inhibitorArginase inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03287271I/IIPlatinum resistant or persistent ovarian cancer (< 3 prior cytotoxic therapies)ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAKView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DefactinibPF-04554878, PF-04554878, VS-6063FAK inhibitor
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
NCT03345485I/IIPlatinum resistant or refractory ovarian cancerA Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid TumorsView DrugsCalifornia, District of Columbia, Illinois, Michigan, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action
TinostamustineEDO-S101HDAC inhibitor
NCT03369223I/IIAdvanced solid tumorsA Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsView DrugsColorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986249Probody of ipilumumabBlocks CTLA-4 inhibition of T cells
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT03386526I/IIAdvanced solid tumors (inc expansion)A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic MalignanciesView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
APG-138SM-138SMAC mimetic and IAP antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelTXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, AnzataxMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT03400332I/IIAdvanced solid tumorsA Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced CancersView DrugsColorado, Maryland, Michigan, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action
BMS-986253IL-8 antagonist
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
NCT02648724I/IIAdvanced solid tumors with MET amplification and WT KRASAn Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor MalignanciesView DrugsColorado, Illinois, Indiana, Nevada, Ohio, Texas
Drug(s) in Trial Other Drug Names Main Known Action
Sym015anti-Met monoclonal antibody mixture Sym015, Hu9006/Hu9338c-Met antagonist
NCT03435640I/IIAdvanced soli